...lymphoma treatmentTG Therapeutics Inc. (NASDAQ:TGTX) said FDA has accepted for Priority Review an NDA for umbralisib...
...– Phosphoinositide 3-kinase deltaCSNK1E (CKI-epsilon) – Casein kinase 1 epsilon BC Staff Ad5-nCoV vosoritide (BMN 111, bmn-111) umbralisib (TGR-1202, rp5264) CanSino...

...NASDAQ:TGTX) climbed $4.23 (34%) to $16.69 on Tuesday after CD20 inhibitor ublituximab plus PI3Kδ inhibitor umbralisib...
...VEGF-A - Vascular endothelial growth factor A BioCentury Staff vadadustat (MT-6548, akb-6548) ADVM-022 (AAV.7m8-aflibercept) ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib (TGR-1202, rp5264) SRI...

...for what could be the third PI3Kδ inhibitor to gain FDA approval, TG Therapeutics said umbralisib...
...UNITY-NHL trial. TG Therapeutics Inc. (NASDAQ:TGTX) gained $1.02 (18%) to $6.80 Monday after reporting that umbralisib...
...Targets: PI3Kδ - Phosphoinositide 3-kinase δ; PI3Kγ - Phosphoinositide 3-kinase γ Sandi Wong, Staff Writer umbralisib (TGR-1202, rp5264) TG...

...supporting the company's decision to seek accelerated approval from FDA by year end for umbralisib (TGR-1202...
...Association for Cancer Research (AACR) meeting in Atlanta, TG Therapeutics Inc. (NASDAQ:TGTX) said once-daily oral umbralisib...
...develop and commercialize umbralisib from Rhizen Pharmaceuticals S.A. (La Chaux-de-Fonds, Switzerland). Brian Moy, Assistant Editor umbralisib (TGR-1202, rp5264) AACR American...

...TG Therapeutics Inc. (NASDAQ:TGTX) said umbralisib (TGR-1202) met the primary endpoint in a cohort of marginal...
...submit an NDA by year end seeking umbralisib's accelerated approval to treat marginal zone lymphoma. Umbralisib...
...IIb data Milestone: Submit NDA (year end 2019); additional Phase IIb data (2019) Brian Moy umbralisib (TGR-1202, rp5264) Rhizen...

...TG Therapeutics Inc. (NASDAQ:TGTX) added $1.61 (31%) to $6.80 on Thursday after reporting that umbralisib (TGR-1202...
...submit an NDA by year end seeking umbralisib's accelerated approval to treat marginal zone lymphoma. Umbralisib...
...India to develop and commercialize umbralisib from Rhizen Pharmaceuticals S.A. (La Chaux-de-Fonds, Switzerland). Brian Moy umbralisib (TGR-1202, rp5264) Rhizen...

...after the company said it will not seek accelerated approval of ublituximab (TG-1101) plus umbralisib (TGR-1202...
...S.A., La Chaux-de-Fonds, Switzerland TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Product: Ublituximab (TG-1101); umbralisib (TGR-1202...
...ongoing Milestone: Phase III data (2019); submit regulatory application (2019) Alicia Parker ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib (TGR-1202, rp5264) TG...

...after the company said it will not seek accelerated approval of ublituximab (TG-1101) plus umbralisib (TGR-1202...
...TG said UNITY-CLL's efficacy data remain blinded. Ublituximab is a glycoengineered mAb against CD20, and umbralisib...
...chlorambucil in both treatment-naïve and relapsed or refractory CLL patients. Alicia Parker ublituximab (TG-1101, TGTX-1101, LFB-R603) umbralisib (TGR-1202, rp5264) TG...

...Fremanezumab Prevent migraine PDUFA date 9/16/18 TG Therapeutics Inc. (NASDAQ:TGTX) / Rhizen Pharmaceuticals S.A. Umbralisib (TGR-1202...

...TG Therapeutics Inc. (NASDAQ:TGTX) said once-daily oral umbralisib (TGR-1202) led to nodal reductions in nearly all...
...Rhizen Pharmaceuticals S.A. (La Chaux-de-Fonds, Switzerland) TG Therapeutics Inc. (NASDAQ:TGTX), New York, N.Y. Product: Umbralisib (TGR-1202...
...Progression-free survival (PFS); safety Status: Phase II data Milestone: Phase III data (2H18) Sandi Wong umbralisib (TGR-1202, rp5264) American...